Magnetic resonance arteriography with dynamic intravenous contrast agents
Patent 5417213 Issued on May 23, 1995. Estimated Expiration Date: June 7, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
600/413, With triggering or gating device424/9.3, Magnetic imaging agent (e.g., NMR, MRI, MRS, etc.)424/9.36, Transition, actinide, or lanthanide metal containing600/419, Of fluid flow600/420, Using detectable material placed in body600/431, Detectable material placed in body600/432Piston-type ram forces material into body
This invention is a method of imaging arteries distinctly from veins using nuclear magnetic resonance imaging in combination with intravenous administration of an magnetic resonance contrast agent. The contrast agent is intravenously injected in such a way that the arterial contrast concentration is substantially higher than the venous and background tissue concentration for a sufficiently long period of time to acquire the magnetic resonance image. The injection site of the contrast agent is chosen such that it is in a vein which is remote from the artery of interest. The magnetic resonance contrast agent may be intravenously infused at a variable infusion rate.
Other References
"Cerebrovascular Magnetic Resonance Angiography", Wesbey et al., J. Vascular Sugery 1992, vol. 16, No. 4, pp. 619-632
"Volume MR Angiography: Methods to Achieve Very Short Echo Times", Schmalbrock et al., Radiology 1990, vol. 175, pp. 861-865
"Three Dimension (Volume) Gradient-Echo Imaging of the Carotid Bifurcation: Preliminary Clinical Experience", Masaryk et al., Radiology 1989, vol. 171, pp. 801-806
"Gadolinium-enhanced Magnitude Contrast MR Angiography of Popliteal and Tibial Arteries", Lossef et al., Radiology 1989, vol. 184, pp. 349-355
"Intracranial Circulation: Preliminary Clinical Results with Three-Dimensional (Volume) MR Angiography", Masaryk et al., Radiology 1989, vol. 171, pp. 793-799
"Contrast Enhancement in Abdominal CT: Bolus us. Infusion", Burgener, et al., AJR, vol. 137, pp. 351-358, 1981
"Optimizing Blood Vessel Contrast in Fast Three-Dimensional MRI", Haacke, et al., SMRM Workshop on MR Imaging of Blood Flow, Mar. 13-14, 1989
"Dynamic Gadolinium-Enhanced 3DFT Abdominal MR Arteriography", Prince et al
"Abdominal Aorta and Renal Artery Stenosis: Evaluation with MR Angiography", Kim, et al., Radiology, vol. 174, pp. 727-731, Mar. 1990
"Intracranial Vascular Lesions: Optimization and Clinical Evaluation of Thre-Dimensional Time-of-Flight MR Angiography", Marchal, et al., Radiology, vol. 175, pp. 443-448, May 1990
"Normal Venous Anatomy of the Brain: Demonstration with Gadopentetate Dimeglumine in Enhanced 3-D MR Angiography", Chakeres, et al., AJR, vol. 156, pp. 161-172, Jan. 1991
"Three-dimensional Time-of-Flight MR Angiography: Applications in the Abdomen and Thorax", Lewin, et al., Radiology, vol. 179, No. 1, pp. 261-264, Apr. 1991
"Safety of Gadolinium-DPTA: Extended Clinical Experience", Niendorf, et al., SMRM Workshop on Contrast Enhanced Magnetic Resonance, May 23-25, 1991
"Fast Time-of-Flight MR Angiography with Improved Background Suppression", Edelman, et al., Radiology, vol. 179, pp. 867-870, Jun. 1991
"Normal Abdominal Enhancement Patterns with Dynamic Gadolinium-enhanced MR Imaging", Mirowitz, et al., Radiology, vol. 180, No. 3, pp. 637-640, Sep. 1991
"Experience with High-Dose Gadolinium MR Imaging in the Evaluation of Brain Metastases", Yuh, et al., AJNR, vol. 13, pp. 335-345, Jan./Feb. 1992
"Frequency Dependence of Tissue Relaxation Times", Bottomly
"Assessment of Carotid Artery Stenosis by MR Angiography: Comparison with X-ray Angiography and ColorCoded Doppler Ultrasound", Anderson, et al., AJNR vol. 13, pp. 989-1003, May/Jun. 1992
"Gadolinium-enhanced High-Resolution MR Angiography with Adaptive Vessel Tracking: Preliminary Result in the Intracranial Circulation", Lin, et al., JMRI, vol. 2, pp. 277-284, May/Jun. 199
June 7, 2013. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
